First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

被引：10
|
作者：
Hirsh, Vera
Yang, James Chih-Hsin
Tan, Eng-Huat
O'Byrne, Ken
Zhang, Li
Boyer, Michael J.
Mok, Tony
Lee, Ki Hyeong
Lu, Shun
Shi, Yuankai
Kim, Sang-We
Laskin, Janessa J.
Kim, Dong-Wan
Arvis, Catherine Dubos
Kolbeck, Karl
Schuler, Martin H.
Massey, Dan
Maerten, Angela
Paz-Ares, Luis
Park, Keunchil
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[4] Natl Canc Ctr, Singapore, Singapore
[5] Princess Alexandra Hosp, Brisbane, Qld, Australia
[6] Queensland Univ Technol, Brisbane, Qld, Australia
[7] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[8] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[9] Chinese Univ Hong Kong, Dept Clin Oncol, Key Lab South China, Hong Kong, Peoples R China
[10] Chungbuk Natl Univ Hosp, Cheongju, North Chungcheo, South Korea
[11] Shanghai Chest Hosp, Shanghai, Peoples R China
[12] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[13] Peking Union Med Coll, Beijing, Peoples R China
[14] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[15] Asan Med Ctr, Seoul, South Korea
[16] BC Canc Agcy, Vancouver, BC, Canada
[17] Seoul Natl Univ Hosp, Seoul, South Korea
[18] Ctr Francois Baclesse, Oncol, Caen, France
[19] Karolinska Univ Hosp, Stockholm, Sweden
[20] Univ Hosp Essen, Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[21] Boehringer Ingelheim Ltd UK, Bracknell, Berks, England
[22] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[23] Hosp Univ Doce Octubre, Madrid, Spain
[24] CNIO, Madrid, Spain
[25] Sungkyunkwan Univ, Canc Med Inst, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9046
引用
收藏
页数：3
相关论文
共 41 条
  • [1] Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: LUX-Lung 7
    Hirsh, Vera
    Park, Keunchil
    Tan, Eng-Huat
    Zhang, Li
    O'Byrne, Kenneth
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Fan, Jean
    Massey, Dan
    Paz-Ares, Luis
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [2] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Park, K.
    Tan, E. H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Hirsh, V.
    Park, K.
    Tan, E. H.
    Zhang, L.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C. H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S. W.
    Laskin, J.
    Kim, D. W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S184 - S184
  • [4] Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC
    Hirsh, V.
    Tan, E.
    Wu, Y.
    Sequist, L.
    Zhou, C.
    Schuler, M.
    Geater, S.
    Mok, T.
    Hu, C.
    Yamamoto, N.
    Feng, J.
    O'Byrne, K.
    Lu, S.
    Huang, Y.
    Sebastian, M.
    Okamoto, I.
    Dickgreber, N.
    Shah, R.
    Palmer, M.
    Maerten, A.
    Massey, D.
    Samuelsen, C.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2231 - S2231
  • [5] First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7
    Park, Keunchil
    Tan, Eng Huat
    Zhang, Li
    Hirsh, Vera
    O'Byrne, Ken
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Lee, Ki Hyeong
    Lu, Shun
    Shi, Yuankai
    Kim, Sang-We
    Laskin, Janessa
    Kim, Dong-Wan
    Laurie, Scott
    Kolbeck, Karl
    Fan, Jean
    Dodd, Nigel
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S335 - S336
  • [6] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
    Schuler, Martin
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Lee, Ki Hyeong
    Lu, Shun
    Shi, Yuankai
    Kim, Sang-We
    Laskin, Janessa
    Kim, Dong-Wan
    Arvis, Catherine Dubos
    Kolbeck, Karl
    Massey, Dan
    Maerten, Angela
    Paz-Ares, Luis
    Park, Keunchil
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) : 1569 - 1579
  • [7] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
    Martin Schuler
    Eng-Huat Tan
    Kenneth O’Byrne
    Li Zhang
    Michael Boyer
    Tony Mok
    Vera Hirsh
    James Chih-Hsin Yang
    Ki Hyeong Lee
    Shun Lu
    Yuankai Shi
    Sang-We Kim
    Janessa Laskin
    Dong-Wan Kim
    Catherine Dubos Arvis
    Karl Kölbeck
    Dan Massey
    Angela Märten
    Luis Paz-Ares
    Keunchil Park
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 1569 - 1579
  • [8] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [9] Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7
    Park, Keunchil
    Tan, Eng Huat
    Zhang, Li
    Hirsh, Vera
    O'Byrne, Ken
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Peil, Barbara
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1214 - S1214
  • [10] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
12345